Arun Sanyal, MD, director of the Institute for Liver Disease and Metabolic Health at VCU Stravitz-Sanyal, discussed clinical trials involving 800 participants, in which weekly doses of semaglutide are effective in treating fatty liver disease.
In a new clinical trial published in the New England Journal of Medicine, scientists using half-Lubin injections were able to reverse life-threatening cases of liver disease.
Semaglutide is traditionally a treatment for type 2 diabetes, which is diagnosed as participants diagnosed with a life form of liver disease called metabolic dysfunction-associated steatohepatitis (MASH).
“This is an important step in the field,” said Arun Sanyal, MD, director of the Institute for Liver Disease and Metabolic Health at VCU. “It offers other options for patients when we consider treating fatty liver disease.”
Joe Rogan gives up drinking for this simple reason
According to WebMD, MASH is a serious form associated with metabolic dysfunction, formerly known as non-alcoholic fatty liver disease.
MASH is a serious form of lipid-schizolid liver disease (MASLD), which was previously known as non-alcoholic fatty liver disease. (iStock)
Both MASH and MASLD are marked by excessive liver fat, which can be dangerous.
"Over time, fat accumulation in the liver can lead to inflammation, liver fibrosis, cirrhosis and liver cancer," the press release for the study said.
Diabetes' first GLP-1 pill for weight loss, showing success in late trials
The researchers chose to study semi-violetglutide as a potential treatment because such drugs have been previously shown to reduce fat and liver scars in people with Mash.
Between 2021 and 2023, 800 randomly selected participants in 37 countries were given weekly Semaglutide or placebo, the press release said. More than half of the diabetes have type 2 diabetes, and about 75% are obese.
Participants treated with half a rupees showed improvements in liver fibrosis measured by liver enzymes and other blood, with a weight loss of 10.5%. (iStock)
After 72 weeks of treatment, 62.9% of participants had less inflammation and fat accumulation in the liver.
In the placebo group, only 34.3% of participants experienced reduced symptoms.
"Under these patients' microscopes, the liver actually starts to look much better," Sanyal noted.
Ozempic, other Semaglutides related to hair loss: That's what you know
The researchers also found that 36.8% of the Semaglutide group had improved liver fibrosis, compared with 22.4% of the placebo group.
Participants treated with half a rupees also saw improvements in liver fibrosis enzymes and blood measurements, with a weight loss of 10.5%.
“I’ve been working in GLP-1 treatment for 16 years and these results are exciting.”
In the semilubin group, some adverse experiences were more common, including nausea, diarrhea, constipation, and vomiting.
“Novo Nordisk continues to explore Semaglutide across metabolic and cardiovascular health, including MASH, MASH, a condition with limited treatment options for patients and healthcare professionals,” said Anna Windle, Senior Vice President of Clinical Development, Medical and Regulatory Affairs at Novo Nordisk, and Maker of Fox Neys, Novo Nordisk, Novo Nordisk, Novo Nordisk, Novo Nordisk, Novo Nordisk, Novo Nordisk.
Click here to sign up for our health newsletter
“We are inspired by these published findings in NEJM, what this may mean for patients. Based on this data, we look forward to working with regulators to bring this potential new treatment option to patients.”
"Although these results must be treated with caution, the analysis shows that half-loopid may be an effective tool for the treatment of this advanced liver disease," the trial head said. (iStock)
"While these results must be treated with caution, the analysis shows that semiglintin can be an effective tool for the treatment of this advanced liver disease," said lead researcher Philip Newsome, director of the Roger Williams Institute of Liver Research at King's College London.
Click here to get the Fox News app
He added: "I have been working in GLP-1 treatment for 16 years and these results are exciting."
Sanyal noted that Semaglutide has been shown to be beneficial for obesity, diabetes and heart disease.
“Now we can add liver disease to that list.”
For more health articles, please visit www.foxnews.com/health
Going forward, the research team plans to collect data from nearly 1,200 participants from 37 countries for up to five years to determine the impact of Semaglutide on long-term liver complications.